Craig Shimasaki, PHD, MBA

Dr. Shimasaki has over 35 years of biotechnology industry experience, starting his career at Genentech. His translational research, development and commercialization work included epitope mapping for an HIV vaccine, SNP-based genetic breast cancer risk prediction biomarkers, a rapid influenza diagnostic, and therapeutic and biologic products for infectious and neuropsychiatric diseases. He co-founded nine companies and led five clinical diagnostic tests through FDA 510(k) approval and is a co-inventor on several patents. He has been involved in raising over $30 million for these companies and participated in taking five companies public in the U.S. and Canadian stock markets. His BS is in Biochemistry from University of California at Davis, PhD in Molecular Biology from the University of Tulsa, MBA from Northwestern University, Kellogg School of Business. He is an Adjunct Professor and Entrepreneur-in-Residence at the University of Oklahoma, Price School of Business and teaches biotechnology entrepreneurship.